What is the current Zepbound prescribing information?

It is the official label for branded Zepbound, revised in August 2026. It covers approved uses, the weekly dose ladder, contraindications, warnings, side effects, drug interactions, pregnancy and breastfeeding, use by age and organ function, clinical studies, and the available pens and vials. It is a reference document, not a personalized dosing plan.

What is the Zepbound starting dose in the package insert?

The label starts Zepbound at 2.5 mg once weekly for four weeks. It calls 2.5 mg an initiation dose, not a maintenance dose. Later increases are in 2.5 mg steps after at least four weeks at the current dose, and the maximum is 15 mg weekly. A prescriber decides the actual pace and maintenance dose.

What is Zepbound's boxed warning?

It concerns thyroid C-cell tumors. Tirzepatide caused these tumors in rats, but the label says it is unknown whether that finding applies to humans. Zepbound is contraindicated with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. The warning does not say every thyroid disorder rules the medicine out.

What are the most common side effects listed for Zepbound?

Stomach and bowel effects lead the list. In the label's pooled weight-reduction trials, nausea affected 25% to 29% across doses, diarrhea 19% to 23%, vomiting 8% to 13%, and constipation 11% to 17%. Abdominal pain and indigestion each reached 9% to 10%. Trial rates describe groups and cannot predict one person's experience.

What changed in the August 2026 Zepbound label?

The current label identifies diabetic retinopathy complications as an August 2026 major change. It says rapid improvement in blood sugar can temporarily worsen existing diabetic retinopathy and calls for monitoring when someone has that history. The same label's change log shows that the earlier warning about suicidal thoughts or behavior was removed in February 2026.

Does the Zepbound label apply to compounded tirzepatide?

No. FDA-approved versions of tirzepatide exist, but the compounded formulation offered here is not FDA-approved. The Zepbound label describes the branded product's formulation, devices, storage, and trial data. It can inform a clinician's review, but a compounded prescription has its own pharmacy label, concentration, directions, and beyond-use date.

Zepbound Prescribing Information, Explained

Zepbound prescribing information is the official, FDA-reviewed guide for the branded tirzepatide injection. In plain English: Zepbound is labeled for long-term weight reduction in certain adults and for moderate-to-severe obstructive sleep apnea in adults with obesity. The label starts at 2.5 mg once weekly, raises doses no sooner than every four weeks, and tops out at 15 mg. It also says the drug must not be used by people with certain thyroid-cancer histories or a serious allergy to tirzepatide.

The document is useful, but it isn't a personal plan. This walkthrough reports label facts; a prescriber sets the actual dose.

What changed in the Zepbound prescribing information

As of September 9, 2026, the day this article was written, the current DailyMed label says Revised: 8/2026. The August change updates the warning about diabetic retinopathy, meaning damage to the light-sensitive tissue at the back of the eye. It now says rapid improvement in blood sugar can temporarily worsen that condition and calls for monitoring when someone already has it.

The same current label records that its earlier warning about suicidal thoughts or behavior was removed in February 2026. That detail matters because older summaries still carry it.

What Zepbound is labeled to treat

An indication is simply a use written into the label. Zepbound has two: long-term weight reduction in adults with obesity, or overweight plus at least one related health condition, and moderate-to-severe obstructive sleep apnea (OSA), repeated pauses or shallow breathing during sleep, in adults with obesity. In both cases, the label pairs the drug with lower calorie intake and more physical activity.

The research behind those uses is product-specific. In the 2022 SURMOUNT-1 trial of 2,539 adults without diabetes, average weight change after 72 weeks was -15.0%, -19.5%, and -20.9% at the three studied maintenance doses, versus -3.1% with placebo (Jastreboff et al., New England Journal of Medicine). In the two 52-week SURMOUNT-OSA trials, the main measure was the number of breathing interruptions per hour; the tirzepatide groups had larger average reductions than placebo (Malhotra et al., New England Journal of Medicine). Those are trial averages, not forecasts for one person.

What the label says about dose

These are label facts, not directions. The starting amount is 2.5 mg under the skin once weekly for four weeks. It is an introduction dose, not a maintenance dose. Later increases are 2.5 mg at intervals of at least four weeks. Maintenance doses for weight reduction are 5, 10, or 15 mg; for OSA they are 10 or 15 mg. The maximum is 15 mg weekly.

For a missed dose, the label allows a four-day window. After more than four days, its schedule skips that dose rather than doubling it. Changing the weekly day requires at least three days between doses. The full tirzepatide dosage schedule explains how prescribers use this ladder and tolerability to make decisions.

The boxed warning and contraindications

A boxed warning is the label's most prominent safety warning. Rats developed thyroid C-cell tumors with tirzepatide; whether that finding applies to humans is unknown.

A contraindication is a reason the drug must not be used. The label names two: a personal or family history of medullary thyroid carcinoma (MTC), a rare thyroid cancer, or multiple endocrine neoplasia syndrome type 2 (MEN 2), an inherited tumor condition; and a previous serious allergic reaction to tirzepatide or a Zepbound ingredient. The warning is specific. It does not say that every thyroid condition is an automatic exclusion.

The warnings, in everyday language

The label asks prescribers to consider several problems that are uncommon but can be serious:

Severe nausea, vomiting, or diarrhea can lead to dehydration and sudden kidney injury.
Gallstones and gallbladder inflammation occurred in the trials. The separate guide to tirzepatide and gallbladder risk owns those numbers and symptoms.
Pancreatitis means an inflamed pancreas; persistent severe abdominal pain is the warning pattern.
Hypoglycemia means blood sugar that is too low. Risk rises with insulin or a sulfonylurea, a type of diabetes pill that increases insulin release.
Existing diabetic retinopathy needs monitoring, the point updated in August 2026.
Pulmonary aspiration means stomach contents enter the lungs during general anesthesia or deep sedation. The label says planned procedures belong in the conversation with the medical team.

The current label does not recommend combining Zepbound with another tirzepatide product or another GLP-1 receptor agonist, a medicine that copies one of the body's after-meal signals. Semaglutide is another GLP-1 option with its own label; a prescriber compares the two against one person's history.

Common adverse reactions by dose

Adverse reactions are side effects recorded during studies. This table comes from the label's pool of two weight-reduction trials, not SURMOUNT-1 alone.

Reaction	Placebo	5 mg	10 mg	15 mg
Nausea	8%	25%	29%	28%
Diarrhea	8%	19%	21%	23%
Vomiting	2%	8%	11%	13%
Constipation	5%	17%	14%	11%
Abdominal pain	5%	9%	9%	10%
Indigestion	4%	9%	9%	10%

Most nausea, vomiting, and diarrhea happened while doses were rising and decreased over time. The broader tirzepatide side-effects guide covers the less common events.

Pregnancy, breastfeeding, age, kidneys, and liver

The label says weight loss offers no benefit during pregnancy and may harm a fetus; human pregnancy data remain too limited to measure the risk. A small lactation study found tirzepatide undetectable or low in milk after one dose, but effects on a breastfed infant and milk production are unknown.

Zepbound has not been established as safe or effective in children. Among adults 65 and older in the weight trials, no overall difference appeared compared with younger adults, though relatively few participants were 75 or older. Kidney or liver impairment does not require a label dose adjustment, but kidney function needs attention if vomiting or diarrhea causes dehydration.

How Zepbound is supplied

The label lists six strengths, from 2.5 through 15 mg. They come as single-dose pens, single-dose vials, four-dose multi-dose vials, and single-patient KwikPens containing four weekly doses. Device instructions and storage times differ, which is why the package directions for the exact presentation matter.

What this label does not say about compounded tirzepatide

The Zepbound label belongs to the branded product. It does not establish the ingredients, concentration, container, storage, or directions for a separately compounded preparation. Promise dispenses tirzepatide as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. The FDA explains that compounded drugs do not receive its premarket review for safety, effectiveness, or quality.

A licensed provider may still prescribe a compounded formulation; that decision is between you and your doctor. At Promise, a licensed provider reviews every request and either prescribes when medically appropriate or declines; not everyone qualifies. The dispensing pharmacy's label and the prescriber's directions govern the preparation actually received.